A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity-Reference-Cited by-同舟云学术

A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity

Published:2017 Issue:3 Volume:5 Page:502-510
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Zhao Dongyang¹²³⁴⁵,Zhang Huicong¹²³⁴⁵,Tao Wenhui¹²³⁴⁵,Wei Wei¹²³⁴⁵,Sun Jin¹²³⁴⁵^ORCID,He Zhonggui¹²³⁴⁵

Affiliation:

1. Department of Pharmaceutics

2. School of Pharmacy

3. Shenyang Pharmaceutical University

4. Shenyang 110016

5. China

Abstract

A rapid albumin-binding 5-FU prodrug has been designed and evaluated. It could form a drug–albumin conjugate nanomedicine for favorable drug delivery after intravenous administration.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2017/BM/C6BM00884D

Reference32 articles.

1. 5-Fluorouracil derivatives: a patent review (2012 – 2014)

2. Multicomponent 5-fluorouracil loaded PAMAM stabilized-silver nanocomposites synergistically induce apoptosis in human cancer cells

3. l-Cysteine conjugated polyl-lactide nanoparticles containing 5-fluorouracil: formulation, characterization, release and uptake by tissuesin vivo

4. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy

5. Human serum albumin: From bench to bedside

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release;Journal of Translational Medicine;2024-07-01

2. Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells;Small;2024-06-03

3. Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions;Frontiers in Cell and Developmental Biology;2024-06-03

4. Advancing Targeted Combination Chemotherapy in Triple Negative Breast Cancer: Nucleolin Aptamer-Mediated Controlled Drug Release;2024-03-27

5. Tuneable redox-responsive albumin-hitchhiking drug delivery to tumours for cancer treatment;Journal of Materials Chemistry B;2024